Article

New IOL designed to reduce variability

St. Petersburg, FL-Lenstec Inc. says the FDA has granted it an investigational device exemption to begin a clinical trial of the Softec HD posterior chamber IOL.

St. Petersburg, FL-Lenstec Inc. says the FDA has granted it an investigational device exemption to begin a clinical trial of the Softec HD posterior chamber IOL.

The lens is an aberration-controlled bi-aspheric IOL designed to replace the crystalline lens following cataract removal. The trial will be based on implants performed on 300 eyes. Enrollment began in November.

The lens is inserted through a 2.5- to 3- mm clear corneal incision using standard posterior chamber IOL insertion techniques. The lens is designed to reduce variability up to 300%, according to the company. Variability is measured as the difference between a lens' labeled prescription and its actual power.

Related Videos
Arun Gulani, MD: How the Gni instrument enhances precision and control in cataract surgery
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.